Heska to Present at Upcoming Conferences in May 2019

LOVELAND, Colo., May 2, 2019 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA) (News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, announced that members of Heska's executive team will be presenting at the following upcoming conferences in May 2019:

• May 15-16, 2019 – Bank of America Merrill Lynch 2019 Healthcare Conference at the Encore Hotel in Las Vegas, NV.  Mr. Kevin Wilson, Heska's CEO & President, will present formally on May 16 at 8:15 a.m. PT.  The audio and slides of the presentation will be available at https://www.veracast.com/webcasts/baml/healthcare2019/id85302488211.cfm and the webcast will be archived for 90 days following the event.  Mr. Wilson will also be available for one-on-one meetings on May 16. 
• May 22-23, 2019 – B. Riley, FBR Institutional Investor Conference at the Beverly Hilton in Los Angeles, CA.  Mr. Jon Aagaard, Heska's Director of Investor Relations, will present formally on May 23 at 12:30 p.m. PT.  Mr. Aagaard will also be available for one-on-one meetings on May 23.
• May 29, 2019 – Stifel 2019 Dental & Veterinary Conference at the Pierre Hotel in New York, NY.  Mr. Wilson, Heska's CEO & President, will present formally on May 29 at 11:30 a.m. ET.  The audio and slides of the presentation will be available at http://wsw.com/webcast/stifel16/hska/ and the webcast will be archived for 90 days following the event.  Mr. Wilson and Ms. Catherine Grassman, Heska's Vice President and Chief Accounting Officer, will also be available for one-on-one meetings on May 29.

For more information, please contact Jon Aagaard at [email protected].

About Heska

Heska Corporation (NASDAQ: HSKA - News) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products. Heska's business is composed of Core Companion Animal Health ("CCA") segment, which represents approximately 85% of revenue, and Other Vaccines, Pharmaceuticals and Products ("OVP") segment, which represents approximately 15% of revenue. CCA segment includes, primarily for canine and feline use, Point of Care Laboratory testing instruments and consumables under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP segment includes, primarily for herd animal health, private label vaccine and pharmaceutical production under third party agreements and channels. For further information on Heska and its products, visit www.heska.com.

SOURCE Heska Corporation

Related Links

http://www.heska.com